Continuous-time multi-type branching processes are fundamental models for expanding and migrating populations with cancer evolution being a prototypical example. Inferring model parameters, like mutation and growth rates, from time-series count data requires efficient computation of population size distributions. Existing methods are mainly based on large-time or large-number asymptotics, which rely on either restricted initial conditions or simplified interactions between cell types. Here, we introduce two numerical approximations of population size distributions for multi-type branching processes on directed graphs with arbitrary initialization. The first approach combines a saddle-point approximation with numerical integration of the probability generating function. We characterize admissibility and establish conditions for saddle-point existence and uniqueness. For directed acyclic graphs, the second approach provides a large-time small-mutation-rate alternative based on closed-form approximate Laplace transforms and efficient numerical inversion. We benchmark the accuracy and speed of both solutions in simulations, showing substantial improvement over the state-of-the-art large-number approximation and orders of magnitude speedup over Gillespie's stochastic simulation algorithm at matching accuracy. We apply our methods to analyze the relapse dynamics of an acute myeloid leukemia patient, where rapid parameter scans over a six-type patient-specific mutation tree quantify how unobserved remission burden and treatment-altered fitness can explain relapse. Our methods provide computational building blocks for future likelihood-based inference in cancer evolution and other expanding populations.
Xiang-Ge Luo, J. Kuipers, N. Beerenwinkel· 0 citations
In women with high-grade serous ovarian cancer, chemotherapy remains the primary standard treatment, despite growing recognition of the disease as highly heterogeneous. Here, we examine the feasibility and clinical utility of comprehensive multimodal molecular profiling to inform treatment decisions. We analyze blood, single-cell and bulk tumor tissue, and malignant ascites using up to eleven technologies (DNA, RNA, protein, and functional assays) within a four-week turnaround time. Hypothetical treatment recommendations are altered for 76% of patients, and multi-omics-guided maintenance therapy is associated with prolonged overall survival in a subset of patients. Subsequent cohort analysis reveals distinct cellular and molecular profiles in ascites-derived single-cells compared to solid tumor tissue, unique per-patient ex vivo drug responses, and a marked increase in cancer cell heterogeneity following chemotherapy exposure. This coincides with genomic signature alterations in whole-genome-amplified patients. Our data suggest that molecularly guided treatments should be tested as adjuvant therapies prior to chemotherapy in the future. High-grade serous ovarian cancer is clinically challenging due to marked molecular heterogeneity and variable treatment response. Here, the authors demonstrate that integrated multimodal tumor profiling can inform personalized maintenance treatment decisions and that chemotherapy reshapes tumor cell diversity.
Francis Jacob, R. Wegmann, Joanna Ficek-Pascual et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.